arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Altimmune, Inc.

ALT Health Care Biotechnology: Pharmaceutical Preparations
$2.12
▼ -4.9% Today
as of Oct 23, 16:45 ET
Last 30 days -35.76% Sep 14 → Oct 23
$2.02 $2.39 $2.76 $3.14 $3.51 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$2.16
High
$2.20
Low
$2.06
Volume
$3M
Avg Vol
$4M
Mkt Cap
$517M
P/E (TTM)
—
Beta
—
52w High
$6.44
52w Low
$2.06
Div Yield
—
Shares Out
$194M

Recent Press Releases & News last 60 days · 7 items

Oct 19 · 12:00 PR GlobeNewswire
Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026
Oct 1 · 11:02 MarketBeat
Altimmune Details Pemvidutide’s Path Toward a Liver-Disease Franchise
Sep 23 · 12:00 PR GlobeNewswire
Altimmune to Participate in Stifel Cardiometabolic Forum
▸ Show all 7 press releases & news Free account →

ALT earnings at a glance

Altimmune, Inc. (ALT) is scheduled to report earnings on Thursday, November 5, 2026 — in 12 days. Analysts expect earnings per share of -$0.14, compared with -$0.21 in the same quarter last year (+33%). The options market is pricing a move of about ±36.5% after the report, a range of roughly $1.35 to $2.89 from today's $2.12. Over its last 6 reports the stock rose the next day 2 times and fell 4, moving ±6.4% on average; after the most recent report on Aug 12, 2026 it moved -2.3%. That means options currently expect more movement than ALT has typically delivered. ALT beat the consensus EPS estimate in 5 of its last 6 reported quarters. Implied volatility is currently 9%. The share price of $2.12 sits near its 52-week low.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$2.06
$6.44
1% of range
Avg surprise (last 6)
+18.2%
Avg reaction (last 6)
-2.4%
33% positive
Latest IV / EM
875%
EM ±36.5% · $3 · Oct 9

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.40$-0.33$-0.26$-0.19$-0.12 Actual $-0.40Actual $-0.32Actual $-0.39Actual $-0.34Actual $-0.35Actual $-0.32Actual $-0.26Est $-0.35Actual $-0.27Est $-0.32Actual $-0.21Est $-0.29Actual $-0.27Est $-0.25Actual $-0.18Est $-0.25Actual $-0.12Est $-0.15 MarJunSepMarJunSepMar/2025Jun/2025Sep/20258KMar/2026Jun/2026
Revenue vs Net Income Revenue Net income
$-23M$-17M$-11M$-6M$5,250 Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Wed Aug 12, 2026Jun/2026 $-0.12 $-0.15 +20.0% +44.4% -2.3% earnings
Wed May 13, 2026Mar/2026 $-0.18 $-0.25 +28.0% +30.8% -1.9% earnings
Thu Mar 5, 20268K 2026-03-05 $-0.27 $-0.25 -8.0% — -17.9% earnings
Thu Nov 6, 2025Sep/2025 $-0.21 $-0.29 +27.6% — +5.1% earnings
Tue Aug 12, 2025Jun/2025 $-0.27 $-0.32 +15.6% — +7.1% earnings
Tue May 13, 2025Mar/2025 $-0.26 $-0.35 +25.7% — -4.2% earnings
Mon Sep 30, 2024Sep 2024 $-0.32 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.35 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.34 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.39 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.32 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.40 — — — — financials

Upcoming

DateFiscalTimeEPS EstLY EPSYoY %Δ
Thu Nov 5, 2026Sep/2026OTHER -$0.14-$0.21 +33.3%

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue———$5,000$5,000$5,000—$5,000
Cost of revenue————————
Gross profit————————
Operating income$-26M$-24M—$-21M$-23M$-22M—$-25M
Net income$-23M$-23M—$-19M$-22M$-20M—$-23M
EPS (diluted)$-0.12$-0.18—$-0.21$-0.27$-0.26—$-0.32

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$63M$98M$44M$61M$183M$49M$37M$31M
Inventory————————
Total current assets$335M$335M$278M$217M$188M$155M$137M$146M
Total assets$527M$336M$280M$218M$190M$157M$139M$148M
Long-term debt$35M$35M$34M$14M$14M———
Total liabilities$53M$52M$55M$33M$29M$15M$16M$14M
Total equity$474M$284M$225M$186M$161M$142M$124M$133M

Implied volatility — last 90 days

59%263%467%671%874% Jun 08 — IV 197% · EM ±16.5%Jun 09 — IV 182% · EM ±13.2%Jun 10 — IV 195% · EM ±11.5%Jun 11 — IV 231% · EM ±9.7%Jun 15 — IV 157% · EM ±11.4%Jun 19 — IV 159% · EM ±17.6%Jun 22 — IV 91% · EM ±7.6%Jun 23 — IV 143% · EM ±10.3%Jun 25 — IV 209% · EM ±8.7%Jun 29 — IV 174% · EM ±41.1%Jun 30 — IV 95% · EM ±22.2%Jul 01 — IV 304% · EM ±12.7%Jul 03 — IV 143% · EM ±15.8%Jul 06 — IV 107% · EM ±8.9%Jul 07 — IV 91% · EM ±6.6%Jul 08 — IV 109% · EM ±6.4%Jul 09 — IV 190% · EM ±8.0%Jul 13 — IV 90% · EM ±7.5%Jul 14 — IV 117% · EM ±8.5%Jul 15 — IV 85% · EM ±5.0%Jul 16 — IV 336% · EM ±14.0%Jul 20 — IV 192% · EM ±16.0%Jul 21 — IV 196% · EM ±14.2%Jul 23 — IV 337% · EM ±14.1%Jul 27 — IV 81% · EM ±6.8%Jul 28 — IV 104% · EM ±7.5%Jul 29 — IV 114% · EM ±6.7%Aug 03 — IV 72% · EM ±10.0%Aug 04 — IV 74% · EM ±9.8%Aug 06 — IV 77% · EM ±9.1%Aug 07 — IV 67% · EM ±7.4%Aug 10 — IV 334% · EM ±27.9%Aug 11 — IV 103% · EM ±7.5%Aug 12 — IV 85% · EM ±5.0%Aug 17 — IV 60% · EM ±5.0%Aug 18 — IV 70% · EM ±5.1%Aug 19 — IV 136% · EM ±8.0%Aug 24 — IV 115% · EM ±9.6%Aug 25 — IV 172% · EM ±12.4%Aug 26 — IV 160% · EM ±9.5%Aug 27 — IV 301% · EM ±12.6%Aug 31 — IV 77% · EM ±6.4%Sep 01 — IV 157% · EM ±11.3%Sep 02 — IV 415% · EM ±24.5%Sep 03 — IV 333% · EM ±13.9%Sep 07 — IV 263% · EM ±21.9%Sep 08 — IV 223% · EM ±16.1%Sep 09 — IV 404% · EM ±23.9%Sep 14 — IV 145% · EM ±12.1%Sep 15 — IV 213% · EM ±15.4%Sep 16 — IV 261% · EM ±15.4%Sep 17 — IV 333% · EM ±13.9%Sep 21 — IV 275% · EM ±23.0%Sep 22 — IV 222% · EM ±16.1%Sep 23 — IV 211% · EM ±12.5%Sep 24 — IV 158% · EM ±6.6%Sep 28 — IV 61% · EM ±14.4%Sep 29 — IV 69% · EM ±16.0%Sep 30 — IV 147% · EM ±8.7%Oct 01 — IV 728% · EM ±30.4%Oct 08 — IV 875% · EM ±36.5%

Sector peers

CAPR
Capricor Therapeutics, Inc.
$520M $5.93+0.8%
OCS
Oculis Holding AG
$508M $7.90+0.4%
PBYI
Puma Biotechnology Inc
$506M $11.02+1.1%
CBIO
Crescent Biopharma, Inc.
$501M $12.82-2.7%
ACRS
Aclaris Therapeutics, Inc.
$500M $3.75-1.6%
ARVN
Arvinas, Inc.
$487M $7.30-3.4%

ALT earnings FAQ

When is ALT's next earnings date?

Altimmune, Inc. is expected to report on November 5, 2026.

What is ALT's expected move for earnings?

Options currently price a move of about ±36.5%, or $0.77 per share either way from $2.12.

How does ALT stock usually react to earnings?

Across the last 6 reports the average next-day move was ±6.4%, up 2 times and down 4 times.

What EPS are analysts expecting from Altimmune, Inc.?

The consensus estimate is -$0.14 per share, versus -$0.21 a year ago.

What is ALT's implied volatility?

ALT's at-the-money implied volatility is about 9% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in